View ValuationMedicover 향후 성장Future 기준 점검 5/6Medicover (는) 각각 연간 29.5% 및 10.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 27.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 20.9% 로 예상됩니다.핵심 정보29.5%이익 성장률27.44%EPS 성장률Healthcare 이익 성장19.4%매출 성장률10.6%향후 자기자본이익률20.94%애널리스트 커버리지Good마지막 업데이트02 Jul 2025최근 향후 성장 업데이트공시 • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.모든 업데이트 보기Recent updates공시 • Jun 20KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital ArmKKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries.공시 • Oct 23Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University HospitalMedicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease.공시 • Oct 03Medicover AB (publ), Annual General Meeting, Apr 29, 2026Medicover AB (publ), Annual General Meeting, Apr 29, 2026.공시 • Jul 24+ 3 more updatesMedicover AB (publ) to Report Fiscal Year 2025 Results on Feb 10, 2026Medicover AB (publ) announced that they will report fiscal year 2025 results at 7:45 AM, Central European Standard Time on Feb 10, 2026공시 • Jun 19Medicover AB (Publ) Announces Executive ChangesMedicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service.공시 • Jun 03Medicover Announces Positive Interim Results from the DART Clinical StudyMedicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort.공시 • Apr 30+ 1 more updateMedicover AB (Publ) Approves Board ElectionsMedicover AB (publ) at its annual general meeting held on 29 April 2025, elected Michael Flemming and Claudia Olsson as new board member.공시 • Oct 30+ 3 more updatesMedicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025Medicover AB (publ) announced that they will report first half, 2025 results on Jul 24, 2025공시 • Oct 02Medicover AB (publ) Announces Nomination Committee for the AGM 2025Medicover AB (publ) publishes the nomination committee's composition for the annual general meeting in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding; Hans Ramel, NG Invest Beta AB; Jannis Kitsakis, Fjärde AP-Fonden; Sophie Larsén, AMF och AMF Fonder. AGM to be held on 29 April 2025. Proposals should be submitted to the nomination committee no later than 11 March 2025.공시 • Oct 01Medicover AB (publ), Annual General Meeting, Apr 25, 2025Medicover AB (publ), Annual General Meeting, Apr 25, 2025.공시 • Aug 14Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during fourth quarter of 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain - one of the leading brands within the Pepco Group (publ). Pepco Group is listed on the Warsaw stock exchange since 2021 with a market cap of over EUR 2.4 billion. Before Pepco, Anand held the position of head of finance at other retail chains such as Halfords and Argos. Anand Patel will replace Joe Ryan, who has served as CFO of Medicover for over 28 years and will be retiring, as announced last year.공시 • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.공시 • Jan 09Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024Medicover announced that Kamila Skorupinski will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services.공시 • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.공시 • Nov 04Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial OfficerJoe Ryan, CFO, has announced that after 28 years with Medicover he will retire from the company during 2024. Joe Ryan will continue in the role until a successor is in place, ensuring continuity. A search process has started.공시 • Sep 21Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024Medicover AB (publ) ("Medicover") publishes the nomination committee's composition for the annual general meeting in 2024. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 27 April 2023, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding, Hans Ramel, NG Invest Beta AB, Jannis Kitsakis, Fjärde AP-Fonden, Angelica Hanson, AMF och AMF Fonder.공시 • Sep 20Medicover AB (publ), Annual General Meeting, Apr 26, 2024Medicover AB (publ), Annual General Meeting, Apr 26, 2024.공시 • Jul 26+ 3 more updatesMedicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024Medicover AB (publ) announced that they will report Q1, 2024 results at 7:45 AM, Central European Standard Time on Apr 26, 2024공시 • Feb 18Medicover AB (publ) Proposes Dividend for 2022Medicover AB (publ) board of directors proposed a dividend for 2022 of €0.12 (€0.12) per share.공시 • Nov 03+ 2 more updatesMedicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023Medicover AB (publ) announced that they will report Q2, 2023 results on Jul 26, 2023공시 • Oct 22Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Medicover AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023이익 및 매출 성장 예측OTCPK:MCVE.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20272,984124193371512/31/20262,71792160318612/31/20252,39965-5227363/31/20252,17131148271N/A12/31/20242,09217140262N/A9/30/20241,99820122240N/A6/30/20241,91123116225N/A3/31/20241,82622113222N/A12/31/20231,7461895205N/A9/30/20231,682890205N/A6/30/20231,610575202N/A3/31/20231,548143186N/A12/31/20221,5101230170N/A9/30/20221,4893745182N/A6/30/20221,4555967195N/A3/31/20221,4428895205N/A12/31/20211,377102115217N/A9/30/20211,29993105202N/A6/30/20211,2269091176N/A3/31/20211,07652104176N/A12/31/20209982683155N/A9/30/20209301475141N/A6/30/2020879453122N/A3/31/20208841631100N/A12/31/2019844232487N/A9/30/2019796192879N/A6/30/2019751193986N/A3/31/2019709204085N/A12/31/201867222N/A74N/A9/30/201864328N/A75N/A6/30/201862026N/A61N/A3/31/201860023N/A55N/A12/31/201758019N/A50N/A9/30/201756010N/A40N/A6/30/20175409N/A36N/A3/31/20175226N/A31N/A12/31/20164974N/A26N/A12/31/20154168N/A29N/A12/31/20143654N/A22N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MCVE.Y 의 연간 예상 수익 증가율(29.5%)이 saving rate(2.9%)보다 높습니다.수익 vs 시장: MCVE.Y 의 연간 수익(29.5%)이 US 시장(18.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: MCVE.Y 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: MCVE.Y 의 수익(연간 10.6%)이 US 시장(연간 13%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MCVE.Y 의 수익(연간 10.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MCVE.Y의 자본 수익률은 3년 후 20.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/07/14 12:54종가2025/04/16 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medicover AB (publ)는 10명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal Colliernull nullABG Sundal Collier SponsoredKristofer Liljeberg-SvenssonCarnegie Investment Bank AB7명의 분석가 더 보기
공시 • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.
공시 • Jun 20KKR Reportedly Eyes at Least $1 Billion Stake in Medicover's India Hospital ArmKKR & Co. Inc. (NYSE:KKR) is in advanced talks to buy a majority stake in the Indian business of Sweden’s Medicover AB (publ) (OM:MCOV B) for at least $1 billion, a source with direct knowledge of the matter said, a deal that would expand its healthcare bet in the world’s most populous nation. Stockholm-listed Medicover issued a press release soon after Reuters sent a request for comment on Wednesday night, saying Medicover Hospitals India (Medicover Healthcare Private Limited) is in discussions with KKR “regarding a potential sale of its Indian operations.”The company did not provide any details and Reuters is first to report that talks are ongoing for KKR to take a majority stake in the Indian business unit for at least $1 billion. Medicover, which entered the country in 2016, operates a network of 26 hospitals with around 6,000 beds. In its statement, it said it has also been preparing for an Indian initial public offering. Sweden’s Medicover owns 66.9 per cent of Medicover Hospitals India. KKR is seeking to acquire the Swedish firm’s entire stake for at least $1.05 billion and is also in discussions with minority shareholders. The “discussions are ongoing and a non-binding agreement has been reached,” said the person, who declined to be named publicly as the talks are private. Medicover did not respond to Reuters queries and KKR declined to comment. In its press release, Medicover said there is no certainty that discussions with KKR will result in any transaction and that the firm is continuing with the IPO process. KKR has been steadily increasing its healthcare investments in India. In 2024, the buyout firm bought a controlling stake in a hospital chain in the southern state of Kerala and has since backed the hospital group’s expansion through acquisitions. India’s hospital sector has attracted strong investor interest as rising incomes, expanding health insurance coverage and growing demand for quality healthcare drive consolidation and capacity expansion across the industry. Medicover competes with Apollo Hospitals, Aster Hospitals, and Fortis Healthcare in India. Rothschild is advising on the sale process, while Kotak is advising KKR, the person added. Kotak and Rothschild did not respond to Reuters queries.
공시 • Oct 23Medicover Announces Additional Results from the Ongoing Dart Clinical Study from Oslo University HospitalMedicover announced additional results from the ongoing DART clinical study from Oslo University Hospital. The study utilises Medicover Genetics' hybrid capture-based, tumour-agnostic MRD assay. The additional results are based on an expanded population within the DART study and further strengthen the value of Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay as a predictor of disease progression in patients with unresectable stage III non-small cell lung cancer (NSCLC). The results were presented through a poster presentation on 18 October 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, where the study was recognised with one of the congress' Best Poster awards. The additional results represent another key milestone towards the clinical validation of Medicover Genetics' MRD assay and commercialisation. The mature data include 640 plasma samples from 84 patients. The study demonstrates that detectable circulating tumour DNA (ctDNA) during and after consolidative durvalumab following chemoradiotherapy (CRT) is strongly associated with inferior progression-free survival (PFS) and can predict disease progression months before radiological evidence. Data from the full 86-patient cohort will follow during the first half of 2026. Detection of ctDNA at six months after the initiation of durvalumab treatment was associated with inferior PFS (HR=2.45; 95% CI: 1.18-5.11; p=0.017). Likewise, detection of ctDNA three months after the end of durvalumab treatment were also associated with inferior PFS (HR=5.37; 95% CI: 1.,93-14.93; p=0.001). Importantly, ctDNA detection preceded imaging-based progression by a median of 7.4 months, demonstrating its potential as an early indicator of disease progression. The DART study (NCT04392505 /EudraCT 2019-002537-11) is a multicentre, prospective phase II trial including 86 patients with unresectable stage II NSCLC across several European centres. The study utilises Medic over Genetics' hybrid capture-based., tumour-agnostic MR DART assay, designed to detect and monitor minimal residual disease.
공시 • Oct 03Medicover AB (publ), Annual General Meeting, Apr 29, 2026Medicover AB (publ), Annual General Meeting, Apr 29, 2026.
공시 • Jul 24+ 3 more updatesMedicover AB (publ) to Report Fiscal Year 2025 Results on Feb 10, 2026Medicover AB (publ) announced that they will report fiscal year 2025 results at 7:45 AM, Central European Standard Time on Feb 10, 2026
공시 • Jun 19Medicover AB (Publ) Announces Executive ChangesMedicover AB (publ) announced Lukasz Krause will assume the role of CDIO as of 1 July 2025 and be part of the executive management team of Medicover. Lukasz brings a wealth of experience in IT management having successfully overseen the IT function for two-thirds of Medicover organisation as Head of IT for the Healthcare Services division over the past three years. He also brings extensive experience in managing IT in reputable international corporations prior to joining Medicover. Lukasz succeeds Jarek Urbanczyk, who is leaving the company after nearly 6 years of service.
공시 • Jun 03Medicover Announces Positive Interim Results from the DART Clinical StudyMedicover announced positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics' minimal residual disease (MRD) assay, MRD can be detected in patients with stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy and durvalumab consolidation. In addition, it was found that detection of MRD during consolidative durvalumab was associated with inferior outcomes. The interim results were presented by Professor Aslaug Helland of Oslo University Hospital at the 2025 ASCO Annual Meeting. The interim results present a key milestone towards clinical validation of Medicover Genetics' MRD assay and commercialization. The DART study is a multicenter phase II clinical trial including 85 patients with unresectable stage III non-small cell Lung cancer (NSCLC) across multiple sites in Europe. All participants received chemoradiotherapy (CRT) followed by durvalumab consolidation therapy. Longitudinal plasma samples were collected at baseline (pre-CRT), at the initiation of durvalumab, and at predefined timepoints during durvalumab treatment and surveillance. The samples were analyzed using Medicover Genetics' novel, tumor-agnostic ctDNA-based MRD assay, which evaluates 293 genes and is tailored to each patient's individual biomarker profile using hybrid capture-based sequencing. The interim analysis included 20 patients who completed all scheduled blood draws, totaling 138 plasma samples. Key findings include: Detectable ctDNA in at least one plasma sample during the first four months after chemoradiotherapy was significantly associated with shorter progression-free survival (PFS) (HR: 4.7; 95% CI: 1.6-13.1; p = 0.004). Presence of ctDNA at four months post-CRT was also linked to shorter progression-free survival (HR: 3.77; 95% CI: 1.,32-10.74; p = 0.013). In contrast, ctDNA detection one month post-CRT was not significantly associated with reduced PFS (HR: 2.23; 95% CI: 0.78-6.36; p = 0.13). detection of ctDNA during the first four months post-CRT were associated with significantly increased odds of death within 24 months (OR: 16.48; 95% CI: 1; 1.29-1000.51; p = 0.017). These findings underscore the potential of ctDNA-basedMRD assessment as a prognostic biomarker to identify high-risk patients and guide more tailored interventions in this population. Ongoing Medicover work regarding the DART study is now focusing on completing the MRD testing for the entire patient cohort.
공시 • Apr 30+ 1 more updateMedicover AB (Publ) Approves Board ElectionsMedicover AB (publ) at its annual general meeting held on 29 April 2025, elected Michael Flemming and Claudia Olsson as new board member.
공시 • Oct 30+ 3 more updatesMedicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025Medicover AB (publ) announced that they will report first half, 2025 results on Jul 24, 2025
공시 • Oct 02Medicover AB (publ) Announces Nomination Committee for the AGM 2025Medicover AB (publ) publishes the nomination committee's composition for the annual general meeting in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding; Hans Ramel, NG Invest Beta AB; Jannis Kitsakis, Fjärde AP-Fonden; Sophie Larsén, AMF och AMF Fonder. AGM to be held on 29 April 2025. Proposals should be submitted to the nomination committee no later than 11 March 2025.
공시 • Oct 01Medicover AB (publ), Annual General Meeting, Apr 25, 2025Medicover AB (publ), Annual General Meeting, Apr 25, 2025.
공시 • Aug 14Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during fourth quarter of 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain - one of the leading brands within the Pepco Group (publ). Pepco Group is listed on the Warsaw stock exchange since 2021 with a market cap of over EUR 2.4 billion. Before Pepco, Anand held the position of head of finance at other retail chains such as Halfords and Argos. Anand Patel will replace Joe Ryan, who has served as CFO of Medicover for over 28 years and will be retiring, as announced last year.
공시 • Jul 25Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Apr 27Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025Medicover AB (publ) provided revenue guidance for year-end 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Feb 09+ 1 more updateMedicover AB (publ) Provides Earnings Guidance for the Financial Year 2025Medicover AB (publ) provided earnings guidance for the financial year 2025. For the period, the company expects organic revenue should exceed €2.2 billion.
공시 • Jan 09Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024Medicover announced that Kamila Skorupinski will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services.
공시 • Nov 05Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025Medicover AB (publ) provided revenue targets for by year-end 2025. For the period, the company announced Organic revenue should exceed €2.2 billion.
공시 • Nov 04Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial OfficerJoe Ryan, CFO, has announced that after 28 years with Medicover he will retire from the company during 2024. Joe Ryan will continue in the role until a successor is in place, ensuring continuity. A search process has started.
공시 • Sep 21Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024Medicover AB (publ) ("Medicover") publishes the nomination committee's composition for the annual general meeting in 2024. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 27 April 2023, consists of: Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family's total shareholding, Hans Ramel, NG Invest Beta AB, Jannis Kitsakis, Fjärde AP-Fonden, Angelica Hanson, AMF och AMF Fonder.
공시 • Sep 20Medicover AB (publ), Annual General Meeting, Apr 26, 2024Medicover AB (publ), Annual General Meeting, Apr 26, 2024.
공시 • Jul 26+ 3 more updatesMedicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024Medicover AB (publ) announced that they will report Q1, 2024 results at 7:45 AM, Central European Standard Time on Apr 26, 2024
공시 • Feb 18Medicover AB (publ) Proposes Dividend for 2022Medicover AB (publ) board of directors proposed a dividend for 2022 of €0.12 (€0.12) per share.
공시 • Nov 03+ 2 more updatesMedicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023Medicover AB (publ) announced that they will report Q2, 2023 results on Jul 26, 2023
공시 • Oct 22Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Medicover AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023